How to Choose Plasma Cell-Free RNA (cfRNA) Extraction Reagents

In molecular biology research and clinical diagnostics, plasma cell-free RNA (cfRNA) is an increasingly valued circulating biomarker. However, cfRNA is extremely scarce, highly labile, and exists in a complex plasma matrix. Efficient, high-quality extraction is therefore the foundation for all downstream analyses.

I. What are peripheral blood, whole blood, serum, and plasma?

vPeripheral blood: Blood circulating in superficial vessels (arteries/veins, capillaries) that can be obtained by routine phlebotomy; contrasted with bone marrow blood, cord blood, etc.

vWhole blood: Unseparated blood = plasma (liquid fraction) + blood cells (RBCs, WBCs, platelets).

vSerum: The supernatant obtained after blood is allowed to clot and then centrifuged; lacks fibrinogen and most coagulation factors.

vPlasma: The supernatant obtained after blood is collected with anticoagulant and centrifuged; retains fibrinogen and coagulation factors.

Sample type	How it is obtained	Anticoagulant added?	Typical uses
Peripheral blood	Circulating blood drawn from peripheral artery/vein or capillary; may be used as whole blood/serum/plasma depending on the assay	Depends on the assay	Clinical tests, flow cytometry, genetic testing, etc.
Whole blood	Used directly without fractionation (for experimental use, anticoagulant is often added to keep it “intact”)	Often yes	CBC, whole-blood PCR, certain immunoassays
Serum	No anticoagulant → clot at room temp → centrifuge and collect supernatant	No	Clinical chemistry, immunoassays for antibodies/hormones/cytokines
Plasma	Add anticoagulant (EDTA/heparin/citrate) → centrifuge and collect supernatant	Yes	Coagulation testing, some chemistry/molecular assays, plasma-derived products

II. Given the very low abundance of plasma cfRNA, which extraction approach should I use?

Plasma cfRNA is extremely low in abundance, fragmented, and easily degraded. Common approaches include: (1) phenol–chloroform/TRIzol-LS organic extraction; (2) silica magnetic-bead methods; (3) silica spin-column methods. All three can yield acceptable cfRNA, but their fit and trade-offs differ:

①Phenol–chloroform (incl. TRIzol-LS)

vBest for: Budget-sensitive research settings or workflows that need to recover RNA plus proteins/metabolites from the same aliquot.

vTips: Add a carrier (glycogen or linear polyacrylamide) and a phase-separation aid (e.g., Phase-Lock Gel); strictly control time/temperature; keep everything RNase-free.

vLimitations: Organic handling and higher inter-batch variability; residual phenol/salts can inhibit RT-qPCR/library prep—wash thoroughly or re-purify.

②Silica magnetic beads

vBest for: Medium to large plasma volumes (typically ≥0.5–4 mL), high-throughput and automation; convenient for parallel processing and upstream/downstream integration.

vTips: Scales linearly by volume; recovery of very short fragments (e.g., miRNA) depends on chemistry and binding salt—review vendor data for small-RNA retention.

vLimitations: Recovery and carryover of inhibitors vary by brand; adjust elution volume and wash stringency to balance yield and purity.

③Silica spin columns

vBest for: Routine volumes (per-column load is typically ~200–600 µL per pass; multiple loads or pooled eluates are possible), manual workflows, and common RT-qPCR/NGS applications.

vTips: Simple process with good reproducibility; options available for total RNA or miRNA-enriched protocols.

vLimitations: Limited load volume; for ≥1 mL plasma, multiple loads or a pre-enrichment step are usually required.

III. Selection criteria for plasma cfRNA kits

(1) High extraction yield

Kit choice directly determines recovery. Poor selection often leads to insufficient RNA concentrations, preventing downstream cloning, nucleic-acid testing (pathogens/genes), sequencing, and hybridization. Prefer products with high recovery and low inhibitor carryover to raise input amounts and method sensitivity—improving overall success from the start.

(2) High RNA purity

Nucleic-acid purity is commonly assessed by A260/A280. Pure RNA is ~2.0 (typically acceptable 1.9–2.1).

vProtein or phenol contamination lowers A260/A280 (<2.0).

vDNA contamination also shifts the ratio toward ~1.8 (lower relative to RNA).

vAlso check A260/A230: ideally >2.0; low values suggest residual salts, sugars, or organics.

Practical tips

vUse low-inhibitor chemistries/columns; follow wash steps carefully and extend drying to remove organics.

vInclude DNase when needed to reduce genomic DNA interference.

vKeep the entire workflow RNase-free: RNase-free disposables, gloves, fast handling, cold storage.

vVerify purity before quantification and downstream work (qPCR, sequencing, hybridization) to improve data reliability.

IV. Representative Aladdin product

RNApure Circulating Reagent (Cat.No.R665870).This product flexibly accommodates different input amounts. It efficiently lyses samples while preserving RNA integrity. The extracted total RNA shows high integrity with no protein or DNA contamination and is suitable for RT-PCR, Northern blotting, molecular cloning, and other downstream applications.

V. Frequently Asked Questions

Q1: How should plasma be stored to avoid cfRNA degradation?

A: cfRNA is highly susceptible to RNase degradation. Separate plasma immediately after blood draw and complete RNA extraction within 2 hours. If immediate processing is not possible, aliquot plasma and store at −80 °C, avoiding repeated freeze–thaw cycles. Use EDTA tubes; avoid heparin, which can inhibit downstream enzymatic reactions.

Q2: Does the plasma input volume strongly affect the outcome?

A: Yes. Because cfRNA is extremely scarce, using ≥200 µL plasma typically helps obtain sufficient RNA. If sample volume is limited, perform multiple extractions and pool the eluates to increase total recovery.

Q3: What if the extracted RNA concentration is too low?

A:

vIncrease starting volume within the recommended reagent ratios.

vReduce elution volume (e.g., from 50 µL to 30 µL) to raise concentration.

vExtend lysis or improve mixing to enhance cfRNA release.

vEnsure reagents are fresh and minimize adsorption losses by using low-bind tubes.

Q4: Why is A260/A230 low?

A: Usually due to residual salts, alcohol, or organics. Add an extra wash or prolong drying spins. If the ratio remains low, check wash volumes and centrifugation parameters.

Q5: Can the extracted RNA be used directly for sequencing or qPCR?

A: Yes, but confirm purity and integrity first. If DNA is present, treat with DNase I. High-purity, high-integrity RNA ensures stable qPCR Ct values and high-quality sequencing data.

In summary, success with plasma cfRNA starts with a solid understanding of sample types and hinges on careful selection of extraction methods and reagents. Given the core challenge of low abundance, a high-recovery, high-purity silica spin-column workflow is a proven, reliable strategy. By evaluating kit yield, purity, and ease of use, researchers can overcome technical bottlenecks and lay a strong foundation for precise gene-expression analyses, pathogen detection, and high-throughput sequencing.

Aladdin: https://www.aladdinsci.com/